Sj. Vyas et Ek. Jackson, ANGIOTENSIN-II - ENHANCED RENAL RESPONSIVENESS IN YOUNG GENETICALLY HYPERTENSIVE RATS, The Journal of pharmacology and experimental therapeutics, 273(2), 1995, pp. 768-777
Renovascular and renal excretory responses to intrarenally infused ang
iotensin II (Ang II) (1 and 3 ng/min, one dose per rat) were assessed
in young (similar to 6 weeks of age) anesthetized spontaneously hypert
ensive rats (SHR) and Wistar-Kyoto (WKY) rats acutely treated with cap
topril. Urinary excretion of cyclic adenosine monophosphate (cAMP) was
also measured in these rats to examine whether Ang II has an enhanced
ability to inhibit adenylate cyclase activity in SHR. Ang II (1 ng/mi
n i.r.a.) significantly reduced renal blood flow (RBF) and increased r
enal vascular resistance (RVR) in SHR but not in WKY rats. At this dos
e, Ang II produced significant decreases in glomerular filtration rate
(GFR), filtration fraction (FF), urine volume (UV) and urinary excret
ion of sodium (UNaV) and potassium (UKV) in SHR without altering any o
f these parameters in WKY rats. Ang II at either dose did not cause an
y increase in systemic blood pressure in either SHR or WKY rats. Ang I
I (3 ng/min i.r.a.) decreased RBF in both SHR and WKY rats to a simila
r extent. However, the higher dose of Ang II produced significant decr
ements in GFR, FF, UV, UNaV and fractional excretion of sodium in SHR
but not in WKY rats. Also, Ang II at both the doses significantly decr
eased urinary cAMP excretion rate in SHR without affecting the same in
WKY rats. These data demonstrate that, even during the developmental
phase of hypertension, the SHR kidney is more responsive to Ang II as
compared with the WKY rat kidney. Also, these results suggest that the
ability of Ang II to inhibit renal adenylate cyclase activity in youn
g SHR may be enhanced. The exaggerated renal reactivity to Ang II may
be an important determinant of the development of hypertension in SHR.